Derma Sciences Launches Wound Treatment Video Series on eLearning Portal
August 02 2011 - 8:30AM
Business Wire
Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and
pharmaceutical company focused on advanced wound care, announces
the launch of a new video series library within the Company’s
eLearning Portal website. The series consists of eight videos
including Derma Sciences Commitment to Advanced Wound Care, as well
as videos about the Company’s leading products; MEDIHONEY®,
XTRASORB®, BIOGUARD®, and ALGICELL® Ag.
Available at www.dermasciences.com/elearning-portal, the
eLearning Portal is designed to provide clinicians and the
Company’s growing sales force with valuable educational programs to
ensure they are kept abreast of the latest information concerning
the Company’s line of advanced wound care products. The new video
series will provide clinicians with detailed product overviews as
well as information for use in clinical applications.
Commenting on the new video series, Derma Sciences CEO Ed Quilty
said, “When we launched the eLearning Portal at the beginning of
2011, our goal was to bring current information to health care
professionals and clinicians striving to deliver the highest
quality care to patients with wounds and burns. These new videos
will help keep our customers current on the benefits and options
within our best-in-class wound management product line.
Facilitating top-quality patient care remains our highest
priority.”
In addition to the video series, the eLearning Portal contains
both new and aggregated content from webinars on such topics as
wound debridement, the use of MEDIHONEY® on stalled wounds and
those with atypical etiologies, and the benefits of super absorbent
polymer technology in moist wound dressings. New webinars are added
approximately every six weeks. The Portal also aggregates the
considerable number of abstracts, articles and peer-reviewed
clinical posters on MEDIHONEY®, as well as broadcast media coverage
about the Company’s products. Additionally, extensive product
literature on MEDIHONEY®, XTRASORB®, ALGICELL® Ag, and BIOGUARD®
are available for download. Clinicians also can request product
samples directly from the Portal.
About Derma Sciences, Inc.
Derma Sciences is a medical technology company focused on three
segments of the wound care marketplace, traditional dressings,
advanced wound care dressings, and pharmaceutical wound care
products. Its MEDIHONEY® product is the leading brand of
honey-based dressings for the management of wounds and burns. The
product has been shown to be effective in a variety of indications,
and was the focus of a positive large-scale, randomized controlled
trial involving 108 subjects with leg ulcers. Other novel products
introduced into the $14 billion global wound care market include
XTRASORB® for better management of wound exudate, and BIOGUARD® for
infection prevention. Derma Sciences has successfully completed a
Phase 2 clinical trial in diabetic foot ulcer healing with DSC127,
a novel pharmaceutical drug under development for accelerated wound
healing and scar reduction. The company is in the process of
preparing for Phase III pivotal studies. For more information
please visit www.dermasciences.com.
Forward-Looking Statements
Statements contained in this news release that are not
statements of historical fact may be deemed to be forward-looking
statements. Without limiting the generality of the foregoing, words
such as "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate" or "continue" are intended to identify
forward-looking statements. Readers are cautioned that certain
important factors may affect the Company's actual results and could
cause such results to differ materially from any forward-looking
statements that may be made in this news release or that are
otherwise made by or on behalf of the Company. Factors that may
affect the Company's results include, but are not limited to,
product demand, market acceptance, impact of competitive products
and prices, product development, completion of an acquisition,
commercialization or technological difficulties, the success or
failure of negotiations and trade, legal, social and economic
risks. Additional factors that could cause or contribute to
differences between the Company's actual results and
forward-looking statements include but are not limited to, those
discussed in the Company's filings with the U.S. Securities and
Exchange Commission.
Derma Sciences, Inc. (NASDAQ:DSCI)
Historical Stock Chart
From Apr 2024 to May 2024
Derma Sciences, Inc. (NASDAQ:DSCI)
Historical Stock Chart
From May 2023 to May 2024